MedTrace Logo

Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years

NCT01824953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3328

Last updated 2013-08-16

No results posted yet for this study

Summary

Serum pepsinogen (PG) levels are considered reliable markers for progression of atrophic gastritis with a stepwise reduction in the serum PG I level or PG I/II ratio. A combination of serum PG levels and Helicobacter pylori serology are used as a biomarker strategy for detection of individuals at increased risk of gastric neoplasm based on Correa's hypothesis. The investigators aimed to uncover whether this combination method could predict the risk of gastric neoplasms and the progression of chronic atrophic gastritis after 3 years. All the participants will be followed for an expected average of 3 years.

Conditions

  • Gastric Neoplasm
  • Gastric Cancer
  • Gastric Adenoma
  • Gastric Atrophy
  • Intestinal Metaplasia

Sponsors & Collaborators

  • Konkuk University Medical Center

    lead OTHER

Principal Investigators

  • Sun-Young Lee, MD · Department of Internal Medicine, Konkuk Universtiy Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01824953 on ClinicalTrials.gov